Sonolisib (PX866)

InvivoChem Cat #:V4886CAS #:502632-66-8Purity >=98%

Description: Sonolisib (also known as PX-866), a wortmannin analog, is a novel, an oral, irreversible, and pan-isoform small-molecule inhibitor of phosphoinositide 3-kinase/PI3K (IC50=0.1 nM (p110alpha), 1.0 nM (p120gamma), 2.9 nM (p110delta)) with with potential antineoplastic activity. antitumor activity. Sonolisib inhibits the production of the secondary messenger phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

References: Mol Cancer Ther. 2005 Sep; 4(9):1349-57.

-20C for 3 years in powder form

Synonym: PX866; PX866; PX 866
Chemical Name: (4S, 4aR, 5R, 6aS, 9aR, E)-1-((diallylamino)methylene)-11-hydroxy-4-(methoxymethyl)-4a, 6a-dimethyl-2, 7, 10-trioxo-1, 2, 4, 4a, 5, 6, 6a, 7, 8, 9, 9a, 10-dodecahydroindeno[4, 5-h]isochromen-5-yl acetate
InChi Key: QIUASFSNWYMDFS-NILGECQDSA-N
InChi Code: InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18, 4)13-19(37-16(3)31)24(22)29(23, 5)21(15-36-6)38-27(17)35/h7-8, 14, 18-19, 21, 34H, 1-2, 9-13, 15H2, 3-6H3/b17-14+/t18-, 19+, 21+, 28-, 29-/m0/s1
SMILES Code: CC(O[CH](C1=C2C(C(O)=C3/C(C(O[CH](COC)[C]13C)=O)=C\N(CC=C)CC=C)=O)C[C]4(C)C(CC[C]42[H])=O)=O